Kuroyama M, Kumano K, Motohashi S, Murase S, Tomonaga F
Department of Pharmacy, Kitasato University Hospital.
Jpn J Antibiot. 1993 Apr;46(4):323-30.
An assessment was made of the serum protein binding of representative oral cephems (cefdinir, cefixime and ceftibuten) for sera from healthy subjects (HS) and patients with chronic renal failure (CRF) using an application of equilibrium dialysis under a same set of conditions in vitro. The protein binding capacity of oral cephems in CRF patients being treated with continuous ambulatory peritoneal dialysis (CAPD) or hemodialysis (HD) was significantly less than that in HS, and a marked increase in free drug concentration was observed. While examining the protein binding of oral cephems with heparin in patients on HD, binding capacity decreased significantly immediately following the completion of dialysis compared to that prior to dialysis. On the other hand, the protein binding of oral cephems did not change when used nafamostat mesilate as an anticoagulant. The addition of palmitic acid (PA), a common non-esterified fatty acid (NEFA), to pooled sera from HS caused the binding capacity of oral cephems to decrease, accompanied by increase in PA concentration. It appears from these findings that changes in the binding capacity of oral cephems with HD have possibly been caused by increase in NEFA due to activation of lipase when heparin was used as an anticoagulant. In conclusion, changes in the protein binding capacity of oral cephems in CRF patients should be taken into consideration in attempts to avoid possible side effects.
在体外相同条件下,采用平衡透析法对健康受试者(HS)和慢性肾衰竭(CRF)患者的血清中代表性口服头孢菌素(头孢地尼、头孢克肟和头孢布烯)的血清蛋白结合情况进行了评估。接受持续非卧床腹膜透析(CAPD)或血液透析(HD)治疗的CRF患者口服头孢菌素的蛋白结合能力明显低于HS患者,且游离药物浓度显著升高。在研究HD患者口服头孢菌素与肝素的蛋白结合情况时,与透析前相比,透析结束后结合能力立即显著下降。另一方面,当使用甲磺酸萘莫司他作为抗凝剂时,口服头孢菌素的蛋白结合情况未发生变化。向HS患者的混合血清中添加常见的非酯化脂肪酸(NEFA)棕榈酸(PA)会导致口服头孢菌素的结合能力下降,同时PA浓度升高。从这些发现来看,当使用肝素作为抗凝剂时,由于脂肪酶激活导致NEFA增加,可能是造成口服头孢菌素与HD结合能力变化的原因。总之,在试图避免可能的副作用时,应考虑CRF患者口服头孢菌素蛋白结合能力的变化。